Patient data
| No | Age (years) | Sex | Pre-MTX | Post-MTX | Pre-MTX | Post-MTX | Pre-MTX | Post-MTX | Pre-MTX | Post-MTX | Dose of MTX (mg/week) | Duration of MTX (months) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visual acuity | Visual acuity | AC | TS (T/d) | OS (mg/day) | ||||||||||
| RE | LE | RE | LE | Cells | Cells | |||||||||
| AC, anterior chamber; OS: oral steroid; TS: topical steroid; nk: dose unknown; sc: subcutaneous | ||||||||||||||
| 1 | 13 | F | 6/6 | 6/6 | 6/5 | 6/5 | 3 | 0 | 6 | 1 | 10 | 4 | 20 | 40 |
| 2 | 15 | F | 6/6 | 6/9 | 6/6 | 6/6 | 4 | 1 | 6 | 2 | 40 | 7 | 30 | 19 |
| 3 | 12 | F | 6/6 | 6/18 | 6/5 | 6/9 | 1 | 1 | 6 | 2 | 30 | 0 | 30 | 24 |
| 4 | 11 | F | 6/6 | 6/6 | 6/5 | 6/6 | 4 | 0 | 6 | 4 | 0 | 0 | 25 | 18 |
| 5 | 10 | F | 6/5 | 6/5 | 6/5 | 6/5 | 1 | 1 | 2 | 2 | 0 | 0 | 20 | 18 |
| 6 | 7 | M | 6/6 | 6/6 | 6/5 | 6/5 | 2 | 2 | 6 | 2 | 10 | 5 | 17.5 | 4 |
| 7 | 16 | F | 6/9 | 6/6 | 6/6 | 6/6 | 1 | 0 | 6 | 0 | nk | 0 | 25 | 21 |
| 8 | 12 | F | 6/6 | 6/9 | 6/6 | 6/5 | 2 | 2 | 4 | 2 | 30 | 7.5 | 25 | 22 |
| 9 | 13 | F | 6/12 | 6/6 | 6/6 | 6/5 | 2 | 0 | 6 | 0 | 40 | 0 | 25sc | 36 |
| 10 | 10 | M | 6/5 | 6/9 | 6/6 | 6/9 | 3 | 0.5 | 8 | 0 | 20 | 5 | 22.5 | 23 |